*The only drug currently approved for this indication is Ranibizuamb. Pegaptanib and Bevacizumab are used off-label
**Corticoids are used off-label. This applies to both intravenous triamcinolone and implantable slow-release devices
***Assuming patient attendance is possible
Figure 4: Treatment algorithm for diffuse and mixed macular edema.